Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Agatolimod - Pfizer

Next Previous
X
Search
Drug Profile

Agatolimod - Pfizer

Alternative Names: Agatolimod sodium; CpG 7909; CPG ODN 2006; CpG oligodeoxynucleotide 7909; PF-3512676; PF-676; ProMune

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Coley Pharmaceutical Group
  • Developer Ohio State University Comprehensive Cancer Center; Pfizer; Stanford University
  • Class Adjuvants; Antineoplastics; Oligodeoxyribonucleotides
  • Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer
  • Discontinued Basal cell cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer

Most Recent Events

  • 11 Mar 2019 No recent reports of development identified for Breast cancer (Combination therapy, Second-line therapy or greater) in USA (SC)
  • 27 Sep 2010 Discontinued - Phase-II for Non-small cell lung cancer in USA (SC)
  • 24 Jun 2010 Agatolimod is still in phase II trials for Non-small cell lung cancer in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top